Skip to main content
SpringerLink
Log in

Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports

  • Case Report
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

To investigate the usefulness of positron emission tomography (PET) in detecting I-131 nonvisualized metastatic foci of well-differentiated thyroid carcinoma (WDTC), 2 patients with papillary and follicular thyroid carcinoma respectively, were studied with I-131 total body scan, thallium-201 scan, Tc99m bone scan and [18F]-2-deoxy-2-fluoro-D-glucose (FDG) PET. Case 1 showed no metastatic lesion in I-131 (up to 150mCi) total body scan, 1 anterior mass in thallium-201 scan, none in Tc99m bone scan and 7 including the main anterior mediastinal mass in FDG-PET. Case 2 showed 2 metastatic lesions in I-131 (150mCi) total body scan, 11 bony metastatic lesions in Tc99m bone scan and 13 in FDG-PET. However, lower extremities were not scanned in FDG-PET. Tumor/background ratio of 1.5 or above is needed to be visualized grossly. The FDG-PET tumor/background ratios are higher than those of thallium-201 except in one site. In conclusion, I-131 scintigraphy is still the first line method to use in detecting WDTC recurrence and metastasis, as I-131 has the advantage of being both a therapeutic and imaging agent. For I-131 nonvisualized metastasis of WDTC, thallium scintigraphy and FDG-PET may be considered. Even though FDG-PET has better sensitivity, resolution imaging and spatial localization, this has to be balanced with its higher cost when compared with thallium scintigraphy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mazzaferri E.L. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97: 418, 1994.

    Article  PubMed  CAS  Google Scholar 

  2. Schlumberger M., Mancusi F., Baudin E., Pacini F. 131 I therapy for elevated thyroglobulin levels. Thyroid 7: 273, 1997.

    Article  PubMed  CAS  Google Scholar 

  3. Wahl R.L., Harney J., Hutchins G.D., Grossman H.B. Imaging of renal cancer using positron emission tomography with 2-deoxy-2- (18F)-fluoro-D-glucose: pilot animal and human studies. J. Urol. 146: 1470, 1991.

    PubMed  CAS  Google Scholar 

  4. Wahl R.L., Cody R.L., Hutchins G.I., Mudgett E.E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179: 765, 1991.

    PubMed  CAS  Google Scholar 

  5. Ichiya Y., Kuwabara Y., Otsuka M., Tahara T., Yoshikai T., Fukumura T., Jingu K., Masuda K. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J. Nucl. Med. 32: 1655, 1991.

    PubMed  CAS  Google Scholar 

  6. Dadparvar S., Krishna L., Brady L.W., Slizofski W.J., Brown S.J., Chevres A., Micaily B. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 71: 3767, 1993.

    Article  PubMed  CAS  Google Scholar 

  7. Meier C.A., Braverman L.E., Ebner S.A., Veronikis I., Daniels G.H., Ross D.S., Deraska D.J., Davies T.F., Valentine M., De Groot L.J., Curran P., McEllin K., Reynolds J., Robbins J., Weintraub B.D. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J. Clin. Endocrinol. Metab. 78: 188, 1994.

    PubMed  CAS  Google Scholar 

  8. Ashcraft M.A., Van Herle A.J. The comparative value of serum thyroglobulin measurements and iodine-131 total body scan in the follow-up study of patients with treated differentiated thyroid cancer. Am. J. Med. 71: 806, 1981.

    Article  PubMed  CAS  Google Scholar 

  9. Pacini F., Lippi F., Formica N., Elisei R., Anelli S., Ceccarelli C., Pinchera A. Therapeutic dose of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin. J. Nucl. Med. 28: 1888, 1987.

    PubMed  CAS  Google Scholar 

  10. Sherman S.I., Tielens E.T., Sostre S., Wharam M.D. Jr, Ladenson P.W. Clinical utility of post-treatment radioiodine scans in the management of patients with thyroid carcinoma. J. Clin. Endocrinol. Metab. 78: 629, 1994.

    PubMed  CAS  Google Scholar 

  11. Pineda J., Lee T., Ain K.J., Reynolds J., Robbin J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scans. J. Clin. Endocrinol. Metab. 80: 1488, 1995.

    PubMed  CAS  Google Scholar 

  12. Pachucki J., Burmeister L.A. Evaluation and treatment of persistent thyroglobulinemia in patients with well-differentiated thyroid cancer. Eur. J. Endocrinol. 137: 254, 1997.

    Article  PubMed  CAS  Google Scholar 

  13. Hisada K., Tonami N., Miyamae T., Hiraki Y., Yamazaki T., Maeda T., Nakajo M. Clinical evaluation of tumor imaging with TI-201 chloride. Radiology 129: 497, 1978.

    PubMed  CAS  Google Scholar 

  14. Brendel A.J., Guyot M., Jeandot R., Lefort G., Manciet G. Thallium-20 1 imaging in the follow-up of differentiated thyroid carcinoma. J. Nucl. Med. 29: 1515, 1988.

    PubMed  CAS  Google Scholar 

  15. Bessell E.M., Foster A.B., Westwood J.H. The use of deoxyfluoro-D-glucopyranoses and related compounds in a study of yeast hexokinase specificity. Biochem. J. 128: 199, 1972.

    PubMed Central  PubMed  CAS  Google Scholar 

  16. Bessell E.M., Thomas P. The effect of substitution at C-2 of D-glucose 6-phosphate on the rate of dehydrogenation by glucose 6-phosphate dehydrogenase (from yeast and from rat liver). Biochem. J. 131: 83, 1973.

    PubMed Central  PubMed  CAS  Google Scholar 

  17. Gallagher B.M., Fowler J.S., Gutterson N.I., Mac-Gregor R.R., Wan C.N., Wolf A.P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2 fluoro-D-glucose. J. Nucl. Med. 19: 1154, 1978.

    PubMed  CAS  Google Scholar 

  18. Dichiro G. Positron emission tomography using 18-F-fluoro-deoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22: 360, 1987.

    Article  CAS  Google Scholar 

  19. Joensuu H., Ahonen A., Klemi P.J. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur. J. Nucl. Med. 13: 502, 1988.

    Article  PubMed  CAS  Google Scholar 

  20. Adler L.P., Bloom A.D. Positron emission tomogrophy of thyroid masses. Thyroid 3: 195, 1993.

    Article  PubMed  CAS  Google Scholar 

  21. Grunwald F., Schomburg A., Bender H., Klemm E., Menzel C., Bultmann T., Palmedo H., Ruhlmann J., Kozak B., Biersack H. Fluorine-18-fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med. 23: 312, 1996.

    Article  PubMed  CAS  Google Scholar 

  22. Feine U., Lietzenmayer R., Hanke J.P., Wohrle H., Muller-Schauemburg W. 18FDG whole-body PET in differentiated thyroid carcinoma, Flipflop in uptake patterns of 18FDG and 131I. Nucl. Med. 34: 127, 1995.

    CAS  Google Scholar 

  23. Feine U., Lietzen Mayer R., Hankie J., Wohrle H., Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med. 37: 1468, 1996.

    PubMed  CAS  Google Scholar 

  24. Dietlein M., Scheidhauer K., Voth E., Theissen P., Schicha H. Fluorine-18-fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur. J. Nucl. Med. 24: 1342, 1997.

    Article  PubMed  CAS  Google Scholar 

  25. Gasparoni P., Rubello D., Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J. Endocrinol. Invest. 20: 527, 1997.

    Article  PubMed  CAS  Google Scholar 

  26. Bronnegard M., Torring O., Boos J., Sylven C., Marcus C., Wallin G. Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic and neoplastic human thyroid tissue. J. Clin. Endocrinol. Metab. 79: 384, 1992.

    Google Scholar 

  27. Robbins R., Ghossein R., Rosai J., Levy O., Carrasco N. Localization of immunoreactive Na+/I− symporter (ir-NIS) in normal and neoplastic thyroid cells. 79th Annual meeting of the Endocrine Society. Abstract P2-32 Minneapolis, Minnesota, U.S.A., June 11–14, 1997.

  28. Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implication for diagnosis and therapy. J. Clin. Endocrinol. Metab. 77: 1090, 1993.

    PubMed  CAS  Google Scholar 

  29. Aktolun C., Bayhan H., Kir M. Clinical experience with Tc-99mMIBI imaging in patients with malignant tumors. Preliminary results and comparison with TI-201. Clin. Nucl. Med. 17: 171, 1992.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, College of Medicine, National Taiwan University, 7 Chung-Shan South Road, Taipei, Taiwan

    Tien-Shang Huang M.D. & C. C. Chang

  2. Department of Radiology, College of Medicine, National Taiwan University, Taipei, Taiwan

    P. U. Chieng & R. F. Yen

Authors
  1. Tien-Shang Huang M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. U. Chieng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. C. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. F. Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, TS., Chieng, P.U., Chang, C.C. et al. Positron emission tomography for detecting iodine-131 nonvisualized metastasis of well-differentiated thyroid carcinoma: Two case reports. J Endocrinol Invest 21, 392–398 (1998). https://doi.org/10.1007/BF03350776

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350776

Key-words

Search

Navigation